La Jolla Pharmaceutical Company
LJPC
LJPC was delisted on the 19th of August, 2022.
45 hedge funds and large institutions have $70.4M invested in La Jolla Pharmaceutical Company in 2022 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 23 reducing their positions, and 3 closing their positions.
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
2% more funds holding
Funds holding: 44 → 45 (+1)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
9% less capital invested
Capital invested by funds: $77.8M → $70.4M (-$7.39M)
74% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$394K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$184K |
| 3 |
OSAM
O'Shaughnessy Asset Management
Stamford,
Connecticut
|
+$147K |
| 4 |
RWM
Ritholtz Wealth Management
New York
|
+$65.5K |
| 5 |
D.E. Shaw & Co
New York
|
+$49.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HP
HealthInvest Partners
Stockholm,
Sweden
|
-$536K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$353K |
| 3 |
Two Sigma Investments
New York
|
-$264K |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
-$134K |
| 5 |
Two Sigma Advisers
New York
|
-$111K |
LJPC Hedge Fund Activity: Q1 2022 in Review
45 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in La Jolla Pharmaceutical Company (LJPC) for Q1 2022, worth a combined $70.4M — down 9.5% from $77.8M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new LJPC positions and 3 closed out — a net gain of 2 holders — while 6 added to existing stakes and 23 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $394K. The largest seller was HealthInvest Partners, cutting an estimated $536K.
- 45 institutional investors held La Jolla Pharmaceutical Company (LJPC) as of Q1 2022, up from 44 in Q4 2021.
- Funds reported $70.4M of La Jolla Pharmaceutical Company stock for Q1 2022, down 9.5% quarter-over-quarter.
- 5 funds opened new La Jolla Pharmaceutical Company positions in Q1 2022 and 3 closed out, a net change of +2 holders.
- The largest La Jolla Pharmaceutical Company buyer in Q1 2022 was Fidelity Investments, an estimated $394K added.
- The largest La Jolla Pharmaceutical Company seller in Q1 2022 was HealthInvest Partners, an estimated $536K sold.
Based on aggregated 13F filings for Q1 2022.